China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
NEW YORK, April 14, 2017 -- Safirstein Metcalf LLP announces that a class action complaint was filed against DaVita Inc. (“DaVita”) (NYSE:DVA) in the U.S. District Court for the District of Colorado. The complaint is brought on behalf of all purchasers of DaVita securities between August 5, 2015 and October 21, 2016 (the “Class Period”) for alleged violations of the Securities Exchange Act of 1934. Safirstein Metcalf is investigating potential breaches of fiduciary duty by management of DaVita resulting from allegations that management may have issued materially misleading business information to the investing public.
If you would like more information about this matter, please contact Sheila Feerick at 1-800-221-0015, or email [email protected].
According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using the American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015
